Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
Journal of clinical oncology
NLM Title Abbreviation
J Clin Oncol
PURPOSE: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We conducted a phase II trial to assess the activity and tolerability of single-agent bevacizumab in recurrent or persistent endometrial cancer (EMC). PATIENTS AND METHODS: Eligible patients had persistent or recurrent EMC after receiving one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of
Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Endometrial Neoplasms/drug therapy/metabolism/mortality, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Salvage Therapy/methods, Vascular Endothelial Growth Factor A/biosynthesis/blood
This document is currently not available here.